Publication Date
11-22-2024
Journal
Nature Communications
DOI
10.1038/s41467-024-53830-0
PMID
39578447
PMCID
PMC11584810
PubMedCentral® Posted Date
11-22-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, Female, Uterine Cervical Neoplasms, Proteogenomics, E1A-Associated p300 Protein, Protein Kinase C beta, Middle Aged, Biomarkers, Tumor, Proto-Oncogene Proteins c-fos, Acetylation, Papillomavirus Infections, Adult, Prognosis, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Cell Proliferation, Protein Processing, Post-Translational, Papillomaviridae, Cervical cancer, Cancer genomics, Tumour biomarkers, Proteomics
Abstract
Although the incidence of cervical cancer (CC) has been reduced in high-income countries due to human papillomavirus (HPV) vaccination and screening strategies, it remains a significant public health issue that poses a threat to women's health in low-income countries. Here, we perform a comprehensive proteogenomic profiling of CC tumors obtained from 139 Chinese women. Integrated proteogenomic analysis links genetic aberrations to downstream pathogenesis-related pathways and reveals the landscape of HPV-associated multi-omic changes. EP300 is found to enhance the acetylation of FOSL2-K222, consequently accelerating the malignant proliferation of CC cells. Proteomic stratification identifies three patient subgroups with distinct features in prognosis, genetic alterations, immune infiltration, and post-translational modification regulations. PRKCB is further identified as a potential radioresponse-related biomarker of CC patients. This study provides a valuable public resource for researchers and clinicians to delve into the molecular basis of CC, to identify potential treatments and to ultimately advance clinical practice.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Genetics and Genomics Commons, Medical Genetics Commons, Medical Molecular Biology Commons, Obstetrics and Gynecology Commons, Oncology Commons, Women's Health Commons